Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors
Researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) have demonstrated that targeting survivin - a protein that inhibits apoptosis or cell death - enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children.